PharmGKB summary: methotrexate pathway. - Wikidata - awgldk - TriplyDB

PharmGKB summary: methotrexate pathway.

PharmGKB summary: methotrexate pathway.

http://www.wikidata.org/entity/Q35115680

about

From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics Pharmacogenomics of chemotherapeutic susceptibility and toxicity Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.Treatment of acute lymphoblastic leukemia from traditional chinese medicine PharmGKB: the Pharmacogenomics Knowledge Base.Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?The genetic architecture of methotrexate toxicity is similar in Drosophila melanogaster and humans.Mathematical modeling of folate metabolism.Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Genome-Wide Screen Reveals sec21 Mutants of Saccharomyces cerevisiae Are Methotrexate-Resistant.Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Pharmacogenetics of childhood acute lymphoblastic leukemia.Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review.Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.An LC-MS chemical derivatization method for the measurement of five different one-carbon states of cellular tetrahydrofolate.Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models.Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.

P2860

Q24632079-C94B6EA8-22DA-453D-B666-B24A6F704626 Q26786582-EB10490F-8207-464A-9410-441B7BB5B475 Q27025558-5B379EAA-F5E7-42FE-B670-3F1F0391B10B Q30418239-F7CF2E50-EE2B-48ED-812B-275B7DAD693E Q33557148-31E12346-D026-4073-8B39-3AF59932E19C Q33632120-31A37F72-0C27-44B4-8E9F-AAABD62480F2 Q33746550-D3F76AD4-C4B9-491B-8026-C601398296CF Q33855594-B207813B-3325-4351-A462-A57AA028E989 Q33914131-22520A5C-E568-4EB4-AB6C-15029F962813 Q35814091-F3DA45E4-F2FC-4D0A-AF4A-7879470FF862 Q37079514-BC062711-B53E-4371-A302-BC0428F5CBC1 Q37100917-B24581FA-95D8-4534-9250-1C72277B43A3 Q37641721-C3315C8C-18ED-4937-BCDC-98B148FEAF83 Q37746482-180951E8-C250-4639-A703-50088F8B5C0D Q38068540-6AA39AB4-9F03-47E2-871A-0D38DF59C673 Q38238947-1CA8ED9F-22C3-4421-9C06-0665F0825C42 Q38243175-166198D9-EA52-417A-97FC-990E3644E972 Q38262203-D0F46722-EF4E-4460-876C-AD9D0A9AFDC4 Q38809116-1410F259-E4BE-4B86-909B-5B15014CAD87 Q38869469-354045EB-FD42-498E-9EFB-1F753350210D Q38886498-2A51D44B-BB67-43D1-BF13-2CE0FDB9F18E Q38888350-3DE9230B-E4E5-4049-A137-288FA5387D7E Q41068390-B1DCBAB8-1825-4BF5-838A-3518922D1B14 Q41846508-4AECE971-AB3F-43CE-85B1-197CC2337E2A Q42199862-B9201F82-41B5-43CC-87E2-20BF9B78E6AE Q42706096-0DA7EC66-FD32-457F-BF41-44D2DF9CA23F Q46322512-93720FD7-7125-4A85-9C1C-2F449FB89190 Q46446111-4E25D12D-0A4E-4FE3-A42D-3769C4A9E01A Q49527931-7BCA2A95-EAD6-49FF-8DCC-639FC48F7D78 Q53093606-8B5A4B20-8B4C-4054-B485-E3BAEE7AD74D

P2860

PharmGKB summary: methotrexate pathway.

http://www.wikidata.org/entity/Q35115680

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

PharmGKB summary: methotrexate pathway.

@ast

PharmGKB summary: methotrexate pathway.

@en

type

label

PharmGKB summary: methotrexate pathway.

@ast

PharmGKB summary: methotrexate pathway.

@en

prefLabel

PharmGKB summary: methotrexate pathway.

@ast

PharmGKB summary: methotrexate pathway.

@en

P1433

Q35115680-1E347B0F-1BED-4F4A-8126-EB0A6FDBFE43

P1476

Q35115680-370D9BDC-AFA9-4AE8-B5F2-E7DF725E3798

P2093

Q35115680-24FC2541-4568-4E14-A5ED-09AA3693BA38

Q35115680-274CE58F-7D4F-49C9-9CEF-D3C05E8F75AD

Q35115680-37D22D75-CC49-4703-9424-7FDE2B831AD7

Q35115680-500745BD-BBF8-4C8D-A131-40EBADEA7CEE

Q35115680-57A58F07-D4D4-4958-99A5-C3BDEE78648B

Q35115680-710FC152-B1AD-4542-ABDF-F6749978CF45

Q35115680-7EEE0FE5-FCBF-4C29-9E12-DA4BF02CE59D

Q35115680-99F453E8-8412-4F74-B78B-1E54DDD41459

Q35115680-A5C12C18-1C0A-44CA-82C0-59489AA79E02

Q35115680-A79EDE0C-7571-462A-9F17-34D695C88572

P2860

Q35115680-02E49C45-7CFC-4225-9279-BAF3486D2442

Q35115680-0316D8E5-CB9F-4242-A47B-1E3E0584072F

Q35115680-03AAED26-3C8F-40A7-9DE0-BCA23F532034

Q35115680-05F4F9FC-BC37-4BB5-835F-F97872271ED1

Q35115680-09B1B9A9-FB48-4C9D-9C12-06411F91C250

Q35115680-0A667A76-6395-44F8-9646-4D90694399B0

Q35115680-0AB82C18-6246-4F01-8228-C952D19260D4

Q35115680-0E29EB45-0571-4FD9-AC98-425A1DE0EA10

Q35115680-11C92469-A7E8-4736-8265-143553BA649F

Q35115680-1242BA33-8BB5-4006-AA56-2821F850192B

P304

Q35115680-4675DD87-03E2-4052-94F3-08A129C75DAE

P31

Q35115680-A4799A40-AA2E-4353-93E9-C3B6CE2335AE

P356

Q35115680-F5DA662B-9F87-41C1-BE4A-DD12D51B9A49

P433

Q35115680-1D000EED-65A3-40A6-B05B-EC92AB1C0409

P478

Q35115680-3A047291-3B83-409E-BC8D-02679628F5D4

P50

Q35115680-00418DEA-EEE5-47F0-AA4D-A0C819A7D19D

Q35115680-6990DDCB-4C02-452A-9029-25F6C583C4DA

Q35115680-8ADD1951-73AE-438B-AD29-D123F71F0397

Q35115680-D5FD1869-0212-4B57-A1F1-6D4F5ECB3A44

P577

Q35115680-12EB783B-0049-41E6-ABE6-A4BAE0943BEB

P698

Q35115680-3A7AE605-FDDD-4764-8274-9D3EBC63FE42

P932

Q35115680-4388C88A-82CF-41D1-A542-7573D7BE9BBD

P356

FPC.0B013E328343DD93

P1433

Pharmacogenetics and Genomics

P1476

PharmGKB summary: methotrexate pathway

@en

P2093

Caroline F Thorn

http://www.w3.org/2001/XMLSchema#string

Cornelia M Ulrich

http://www.w3.org/2001/XMLSchema#string

Deborah French

http://www.w3.org/2001/XMLSchema#string

Howard L McLeod

http://www.w3.org/2001/XMLSchema#string

James Steven Leeder

http://www.w3.org/2001/XMLSchema#string

Kathy Giacomini

http://www.w3.org/2001/XMLSchema#string

Leo Kager

http://www.w3.org/2001/XMLSchema#string

Mara L Becker

http://www.w3.org/2001/XMLSchema#string

Mary V Relling

http://www.w3.org/2001/XMLSchema#string

Russ B Altman

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1

Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption

Molecular action of methotrexate in inflammatory diseases

Treating childhood acute lymphoblastic leukemia without cranial irradiation

Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates

Anticancer antifolates: current status and future directions

Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia

Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis

In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile

Human liver methenyltetrahydrofolate synthetase: improved purification and increased affinity for folate polyglutamate substrates

P304

679-686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E328343DD93

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Henry M. Dunnenberger

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21317831

http://www.w3.org/2001/XMLSchema#string

P932

3139712

http://www.w3.org/2001/XMLSchema#string